Clinical Trial: A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024641) titled 'A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection' on April 30.

Brief Summary: The primary purpose of this study is to assess the safety and tolerability of single and multiple intravenous (IV) doses of GIGA-2339 in participants with chronic Hepatitis B Virus (HBV) infection.

Study Start Date: Nov. 13, 2024

Study Type: INTERVENTIONAL

Condition: Hepatitis B Virus Infection

Intervention: DRUG: GIGA-2339

Administered by intravenous infusion

DRUG: Placebo

Administered by intravenous infusion

Recruitment Status: RECRUITING

Sponsor: GigaGen, In...